Syndax Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Date: December 1, 2010
Pages: 35
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: S116A8395F6EN
Leaflet:

Download PDF Leaflet

Syndax Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Syndax Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Syndax Pharmaceuticals, Inc. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Syndax Pharmaceuticals, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Syndax Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Syndax Pharmaceuticals, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Syndax Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Syndax Pharmaceuticals, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Syndax Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Syndax Pharmaceuticals, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Syndax Pharmaceuticals, Inc. and identify potential opportunities in those areas.
Syndax Pharmaceuticals, Inc. Snapshot
Syndax Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Syndax Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Syndax Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Syndax Pharmaceuticals, Inc. – Pipeline Products Glance
Syndax Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Syndax Pharmaceuticals, Inc. – Drug Profiles
SNDX 275
  Product Description
  Mechanism of Action
  R&D Progress
SNDX-275 + Aromasin
  Product Description
  Mechanism of Action
  R&D Progress
Tarceva + SNDX-275
  Product Description
  Mechanism of Action
  R&D Progress
Syndax Pharmaceuticals, Inc. – Pipeline Analysis
Syndax Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Syndax Pharmaceuticals, Inc. Pipeline Products By Target
Syndax Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Syndax Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Syndax Pharmaceuticals, Inc. – Recent Pipeline Updates
Syndax Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Oct 15, 2010: Syndax Pharmaceuticals Receives UK Patent For Entinostat
Oct 15, 2010: Syndax Pharmaceuticals Receives UK Patent For Entinostat
Oct 15, 2010: Syndax Pharmaceuticals Receives UK Patent For Entinostat
Oct 15, 2010: Syndax Pharmaceuticals Receives UK Patent For Entinostat
Oct 15, 2010: Syndax Pharmaceuticals Receives UK Patent For Entinostat
Apr 13, 2007: Syndax Pharmaceuticals Enters Into Licensing Agreement With Bayer Schering Pharma AG.
Financial Deals Landscape
Syndax Pharmaceuticals, Inc., Deals Summary, 2004 to 2010
Syndax Pharmaceuticals, Inc. Detailed Deal Summary
Venture Financing
Syndax Pharmaceuticals Raises $9 Million In Series A Financing
Syndax Pharmaceuticals Secures $40 Million In Series A Financing
Licensing Agreements
Syndexa Pharmaceuticals Enters Into Licensing Agreement With Bayer Schering Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 35

LIST OF TABLES

Syndax Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2010
Syndax Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2010
Syndax Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2010
Syndax Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2010
Syndax Pharmaceuticals, Inc. - Phase II, 2010
Syndax Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2010
Syndax Pharmaceuticals, Inc. - Pipeline By Target, 2010
Syndax Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2010
Syndax Pharmaceuticals, Inc. – Pipeline By Molecule Type, 2010
Syndax Pharmaceuticals, Inc. – Recent Pipeline Updates, 2010
Syndax Pharmaceuticals, Inc., Deals Summary, 2004 to 2010
Syndax Pharmaceuticals Raises $9 Million In Series A Financing
Syndax Pharmaceuticals Secures $40 Million In Series A Financing
Syndexa Pharmaceuticals Enters Into Licensing Agreement With Bayer Schering Pharma 33

LIST OF FIGURES

Syndax Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2010
Syndax Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2010
Syndax Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2010
Syndax Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2010
Syndax Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2010
Syndax Pharmaceuticals, Inc. - Pipeline By Target, 2010 19

Ask Your Question

Syndax Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: